Mucoadhesive Chitosan-Polyacrylic Acid Complex for GI Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mucoadhesive drug carriers comprising poly-ionic complexes of chitosan and polyacrylic acid face limitations in retention time in the gastrointestinal tract, pH-dependent drug dissolution, and production constraints, hindering their application as effective oral formulations.
Innovation Solution
A mucoadhesive pharmaceutical composition comprising a micronized poly-ionic complex of chitosan and polyacrylic acid, combined with a water-soluble polymer, which is produced using conventional pharmaceutical facilities and exhibits enhanced mucoadhesiveness and pH-independent drug release, allowing for increased retention time and controlled release of active ingredients in the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If chitosan is used as a mucoadhesive polymer in oral formulations, then mucoadhesiveness is improved, but the formulation dissolves completely in acidic gastric environment
Solution Approach 1:
The patent combines chitosan with polyacrylic acid to form a poly-ionic complex. This composite material leverages the mucoadhesive properties of chitosan while the polyacrylic acid component provides resistance to acidic dissolution, creating a formulation that maintains both adhesion strength and environmental stability in the gastric environment.
2Stability of the object's composition
If polyacrylic acid is used to prevent dissolution in acidic condition, then formulation stability is improved, but viscosity decreases at low pH
Solution Approach 1:
The patent merges chitosan and polyacrylic acid into a poly-ionic complex where the components complement each other's deficiencies. The complex structure allows the formulation to maintain adequate viscosity in acidic conditions while preventing complete dissolution, as the combined polymer structure behaves differently than the individual components alone.
3Duration of action of moving object
If micronized poly-ionic complex is used for sustained release, then retention time is improved, but production complexity increases
Solution Approach 1:
The patent utilizes micronization to change the physical parameter of particle size of the poly-ionic complex. This parameter change enhances mucoadhesiveness and prolongs retention time in the gastrointestinal tract. The micronized form can be produced using conventional pharmaceutical facilities through processes like freeze-drying and milling, making the enhanced performance achievable without requiring entirely new production infrastructure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively prolongs the retention time of active ingredients in the gastrointestinal tract, ensuring sustained release and improved bioavailability, while being producible on a larger scale using conventional methods, overcoming previous limitations in pH dependence and production complexity.
Implementation Method 1
Chitosan has good mucoadhesiveness, which is known to mainly result from charge interaction, i.e. charge interaction between cations of chitosan and anions of gastro-intestinal surface
Implementation Method 2
increasing the retention time in gastro-intestinal tract due to mucoadhesiveness particularly in gastro-intestinal tract and swelling property
Data Source
AI summary
Disclosed is a mucoadhesive pharmaceutical composition comprising a poly-ionic complex of chitosan and a polyacrylic acid polymer. As an oral formulation, the composition has the extended retention time in the gastrointestinal tract by its mucoadhesive and swelling properties, which is useful as sustained release formulations, retentive formulations of active ingredients with limited absorption regions, and active ingredients with pH dependent solubility.